peginterferon beta-1a

Ligand id: 7637

Name: peginterferon beta-1a

No information available.
Summary of Clinical Use
Approved for the treatment of relapsing-remitting multiple sclerosis. See Calabresi et al (2014) [2] for the reults of the phase III ADVANCE clinical trial. (NCT00906399).
Mechanism Of Action and Pharmacodynamic Effects
Interferon-beta-1a reduces the auto-immune attack on the protective sheath around the nerves which causes MS flare-ups, and thus reduces relapses. PEGylation of the cytokine increases the circulating half-life of the cytokine and thereby extends the administration interval to bi-weekly.